The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

With a market cap of $191.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics for a wide range of diseases, including cancer, cardiovascular conditions, and autoimmune disorders. It markets leading medicines such as Enbrel, Prolia, and Repatha while collaborating with partners like AstraZeneca plc and UCB to expand its pipeline and global reach.

The Thousand Oaks, California-based company is expected to release its fiscal Q1 2026 results after the market closes on Thursday, Apr. 30. Ahead of this event, analysts expect AMGN to report an adjusted EPS of $4.75, down 3.1% from $4.90 in the prior year's quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarters.

Tesla Earnings, Hormuz and Other Key Things to Watch this Week

Netflix Generates Massive FCF and FCF Margins - NFLX Price Targets Are Higher

Profit Jumped 58% at Taiwan Semi. Does That Make TSM Stock a Buy Here?

Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!

For fiscal 2026, analysts forecast the world's largest biotech drugmaker to post adjusted EPS of $22.18, a 1.6% rise from $21.84 in fiscal 2025. Moreover, adjusted EPS is projected to grow 4.8% year-over-year to $23.24 in fiscal 2027.

AMGN stock has increased 27.1% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 34.6% gain. Nevertheless, the stock has outperformed the State Street Health Care Select Sector SPDR ETF's (XLV) 9.5% rise over the same period.

Shares of Amgen jumped 8.2% following its Q4 2025 results on Feb. 3, reporting stronger-than-expected $9.9 billion in revenue and adjusted EPS of $5.29. Investor confidence was further boosted by strong forward guidance, with 2026 adjusted EPS projected at $21.60 - $23 and full-year revenue of $37 billion - $38.4 billion, slightly ahead of Wall Street expectations. Additionally, optimism around Amgen’s obesity pipeline, particularly MariTide, in six Phase 3 trials and positioned as a less-frequent alternative to weekly GLP-1 drugs, reinforced the stock’s rally.

Analysts' consensus rating on AMGN stock is cautiously optimistic, with a "Moderate Buy" rating overall. Out of 35 analysts covering the stock, opinions include 13 "Strong Buys,” two "Moderate Buys," 17 "Holds,” one "Moderate Sell," and two "Strong Sells.” The average analyst price target for AMGN is $357.57, suggesting a potential upside of 1.6% from current levels.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com